Fed-batch method of making anti-TNF-alpha antibody
View Patent ↗The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
1. A fed-batch method for making an anti-TNFα antibody comprising a light chain variable region (LCVR) comprising the sequence of SEQ ID NO:1 and a heavy chain variable region (HCVR) comprising the sequence of SEQ ID NO:2, said method comprising culturing mammalian cells comprising a nucleic acid encoding said anti-TNFα antibody in a cell culture production medium in large scale, wherein the pH of the cell culture production medium is adjusted such that the culturing begins at a starting pH and ends at a final pH that is less than the starting pH, such that said anti-TNFαantibody is produced at a titer of at least 2 g/L in said cell culture production medium.
2. The fed-batch method according to claim 1 , wherein the starting pH is 8 or less.
3. The fed-batch method according to claim 1 , wherein the final pH is 6.5 to 7.0.
4. The fed-batch method according to claim 3 , wherein the starting pH is 8 or less.
5. The fed batch method according to claim 1 , wherein the starting pH is 7.1 to 7.2.
6. The fed-batch method according to claim 1 , wherein the final pH is 6.9.
7. The fed-batch method according to claim 1 , wherein the starting pH is 6.5 to 8 and the final pH is 6.5 to 7.
8. The fed-batch method according to claim 1 , wherein the starting pH is 7.1 and the final pH is 6.9.
9. The fed-batch method according to claim 1 , wherein the pH is adjusted over a period of at least 24 hours.
10. The fed-batch method according to claim 1 , wherein the pH is adjusted within the first 72 hours of the culturing.
11. The fed-batch method according to claim 1 , further comprising supplementing the cell culture production medium, wherein the pH is adjusted prior to the supplementing.
12. The fed-batch method according to claim 1 , wherein the mammalian cells are Chinese Hamster Ovary (CHO) cells.
13. The fed-batch method according to claim 1 , wherein the mammalian cells are cultured at a first temperature, wherein said first temperature under which the mammalian cells are cultured is then reduced to a second temperature prior to initiating feeding of the mammalian cells with a feed solution.
14. The fed-batch method according to claim 13 , wherein: (i) the first temperature is 37° C. and the second temperature is 33° C.; (ii) the first temperature is 37° C. and the second temperature is 32° C.; or (iii) the first temperature is 35° C. and the second temperature is 32° C.
15. The fed-batch method according to claim 1 , wherein glucose concentration in said cell production medium is monitored, the glucose concentration in said medium decreases to below 2 g/L, and glucose is added to said medium when the glucose concentration in said medium decreases to below 2 g/L, or the glucose concentration in said medium is monitored and glucose is added to said medium to maintain the glucose concentration in said medium at a concentration of at least 2 g/L but no greater than 7 g/L.
16. The fed batch method according to claim 1 , wherein said produced anti-TNFα antibody is affinity purified using a Protein A resin.
17. A fed-batch method for making adalimumab, said method comprising culturing mammalian cells comprising a nucleic acid encoding said adalimumab in a cell culture production medium in large scale, wherein the pH of the cell culture production medium is adjusted such that the culturing begins at a starting pH and ends at a final pH that is less than the starting pH, such that said adalimumab is produced at a titer of at least 2 g/L in said cell culture production medium.
18. The fed-batch method according to claim 17 , wherein the starting pH is 8 or less.
19. The fed-batch method according to claim 17 , wherein the final pH is 6.5 to 7.0.
20. The fed-batch method according to claim 17 , wherein the starting pH is 7.1 to 7.2.
21. The fed-batch method according to claim 17 , wherein the starting pH is 6.5 to 8 and the final pH is 6.5 to 7.
22. The fed-batch method according to claim 17 , wherein the starting pH is 7.1 and the final pH is 6.9.
23. The fed-batch method according to claim 17 , wherein the pH is adjusted over a period of at least 24 hours.
24. The fed-batch method according to claim 17 , wherein the pH is adjusted within the first 72 hours of the culturing.
25. The fed-batch method according to claim 17 , further comprising supplementing the cell culture production medium, wherein the pH is adjusted prior to the supplementing.
26. The fed-batch method according to claim 17 , wherein the mammalian cells are Chinese Hamster Ovary (CHO) cells.
27. The fed-batch method according to claim 17 , wherein the mammalian cells are cultured at a first temperature, wherein said first temperature under which the mammalian cells are cultured is then reduced to a second temperature prior to initiating feeding of the mammalian cells with a feed solution.
28. The fed batch method according to claim 27 , wherein: (i) the first temperature is 37° C. and the second temperature is 33° C.; (ii) the first temperature is 37° C. and the second temperature is 32° C.; or (iii) the first temperature is 35° C. and the second temperature is 32° C.
29. The fed-batch method according to claim 17 , wherein glucose concentration in said cell production medium is monitored, the glucose concentration in said medium decreases to below 2 g/L, and glucose is added to said medium when the glucose concentration in said medium decreases to below 2 g/L, or the glucose concentration in said medium is monitored and glucose is added to said medium to maintain the glucose concentration in said medium at a concentration of at least 2 g/L but no greater than 7 g/L.
30. The fed batch method according to claim 17 , wherein said produced adalimumab is affinity purified using a Protein A resin.